Merck has announced the acquisition of Verona Pharma for 10 billion dollars, strengthening its portfolio of respiratory treatments.
Raluca Ioana Draghici
.webp)
Economy
www.shutterstock.com
Always see our news on Google
Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
07:40
The Parliament is convened for a new extraordinary session between August 3 and 6 for the approval of the National Strategy for Biodiversity Conservation.
07:22
The USA and Japan, the first joint intervention in the yen market since 2011
07:09
Superliga: Rapid Bucharest defeats CFR Cluj 3-1 and climbs to first place in the standings
23:21
The option of a technocratic government could return to the negotiating table. Ciprian Ciucu: "The President would have tested one or two, three options, but I was not told what those options are."
22:53
The President of Brazil, Lula da Silva, is launching his campaign for a fourth term / He declares himself to be "in excellent shape" at the age of 80.
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
